Amycretin (NN 9487) is an innovative dual agonist targeting both GLP‑1 and amylin pathways. Developed by Novo Nordisk, this novel drug available in both injectable and oral forms and holds significant promise for weight management. Let look at the its effectiveness based on current clinical research.

Impressive Weight Loss Results

Injectable Amycretin (Phase 1b/2a Study)

In a randomized, placebo-controlled trial involving adults with BMI 27–39.9 kg/m², participants received weekly subcutaneous injections for 36 weeks.
Those on the full 60 mg dose lost an average 24.3% of body weight vs. –1.1% for placebo
Other doses also yielded significant reductions:
- 20 mg → –22.0%
- 5 mg → –16.2%
- 1.25 mg → –9.7%

These results exceed those from Wegovy (semaglutide), which showed ~14.9% weight loss over 68 weeks

Oral Amycretin

In a first-in-human study, participants taking daily oral doses up to 100 mg experienced up to 13.1% weight loss in just 12 weeks versus ~1.2% with placebo

How Does That Compare to Other Treatments?

Medication	Duration	Mean Weight Loss
Injectable Amycretin	36 weeks	24.3%
Oral Amycretin	12 weeks	13.1%
Wegovy (semaglutide)	68 weeks	14.9%
Ozempic (GLP-1 RA)	Varies	Similar to Wegovy
Mounjaro (tirzepatide)	≈88 weeks	25.3%

Injectable Amycretin leads the pack in short-term reduction.
Mounjaro is comparable in long-term, but Amycretin’s results come faster

Is There a Weight-Loss Plateau?

Injectable Amycretin showed no plateau by week 36 participants continued losing weight into maintenance phases
Long-term data (beyond 36 weeks) are still pending, but early signs are promising.

Why Amycretin Might Work Faster

As a dual agonist, it targets drive hunger suppression via GLP‑1 and satiety/metabolism through amylin.
This combination may enhance efficacy and speed plus, oral delivery could improve convenience and compliance

What You Should Know

Short-term superiority: Injectable Amycretin outperforms current GLP‑1 options in 36 weeks.
Oral potential: High-dose pills deliver >13% loss in just 12 weeks.
Awaiting Phase 3: Full regulatory approval and long-term safety data are still pending
Side effects similar to GLP‑1 drugs: Gut issues like nausea are common; generally mild to moderate

Bottom Line

Amycretin offers promising and rapid weight loss:

Up to 24% with weekly injections in under a year.
Over 13% via pills in just three months.

If future phase 3 trials confirm its safety and durability, Amycretin could revolutionise obesity care for both long-term and early responders.

Amycretin:

1. What is Amycretin?

Amycretin is a next-generation weight loss medication currently in clinical development by Novo Nordisk. It is a dual agonist that targets both the GLP-1 and amylin receptors to help reduce appetite, slow gastric emptying, and increase feelings of fullness. It is being investigated as both an injectable and oral treatment.

2. How does Amycretin help with weight loss?

Amycretin mimics the effects of two naturally occurring hormones: GLP-1 and amylin. Together, these regulate appetite, reduce food intake, and delay digestion. Clinical trials have shown that Amycretin leads to significant reductions in body weight in both its oral and injectable forms.

3. How effective is Amycretin compared to other medications?

In a 36-week study, participants on the 60mg injectable dose of Amycretin lost an average of 24.3% of their body weight. This is higher than the weight loss results seen with Wegovy (14.9% after 68 weeks) and similar to Mounjaro (25.3% after 88 weeks).

4. What are the common side effects of Amycretin?

Side effects are similar to other GLP-1-based medications and include:

Nausea
Diarrhoea
Vomiting
Fatigue
Headache

5. Is Amycretin approved for use in the UK?

As of now, Amycretin is still undergoing clinical trials and is not yet approved for general use in the UK. It is expected to be launched later this decade, potentially before 2030, pending successful Phase 3 trials and regulatory approval.

6. When will Amycretin be available in UK pharmacies?

The exact launch date has not been confirmed. Novo Nordisk aims to release Amycretin before 2030. MedCare Health Clinic & Pharmacy will be among the providers to offer consultations and private prescriptions once the medication is approved.

7. Can I get an Amycretin prescription online in the UK?

Once approved, MedCare Health Clinic will provide online consultations and private prescriptions for eligible patients.

8. Who is eligible to use Amycretin?

Eligibility will likely follow similar criteria to current GLP-1 medications:

Adults with a BMI ≥30kg/m²
Adults with a BMI ≥27kg/m² and at least one weight-related condition (e.g. type 2 diabetes, high blood pressure)
Eligibility criteria will be confirmed once the drug is licensed.

9. Is Amycretin safe for people with diabetes?

Amycretin is currently being evaluated for both weight loss and type 2 diabetes treatment. Early data suggest it may be suitable for people with diabetes, but safety profiles will be confirmed once trials conclude.

10. How much does Weight Loss pill cost?

Pricing has not yet been announced for Amycretin. However Orlistat weight loss capsules are the only approved oral form currently available which are designed to aid weight loss in adults with. Orlistat works by reducing the amount of fat your body absorbs from food, making it an effective option for weight management when combined with a calorie-controlled diet and regular exercise. T

11. Will I need to follow a diet while on Amycretin?

While Amycretin helps control appetite, combining treatment with a balanced diet and exercise plan is always recommended for the best results. MedCare Health Clinic provides full lifestyle support with each prescription.

12. What if I experience side effects?

If you experience side effects, speak to your healthcare provider. MedCare patients receive follow-up support to help manage side effects and adjust treatment plans as needed.

Still have questions?
Contact MedCare Health Clinic or visit medcare-healthclinic.com to register your interest and be notified when Amycretin becomes available in the UK.